instruction stringlengths 22 145 | input stringclasses 1
value | answer stringlengths 220 325 | text stringlengths 382 597 |
|---|---|---|---|
Median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)? | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pan... | |
Comparison of the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combinati... | |
The impact of patient characteristics on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).
### Response:
The median progression-free survival (PFS) for the treatment combination ... | |
The role of genetic factors in the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Panobin... | |
The influence of previous treatments on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).
### Response:
The median progression-free survival (PFS) for the treatment combination o... | |
The effect of dosage and administration frequency on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).
### Response:
The median progression-free survival (PFS) for the treatment ... | |
The correlation between the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment co... | |
The impact of side effects and adverse reactions on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).
### Response:
The median progression-free survival (PFS) for the treatment c... | |
The role of supportive care in improving the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).
### Response:
The median progression-free survival (PFS) for the treatment combination ... | |
The influence of disease stage at the start of treatment on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).
### Response:
The median progression-free survival (PFS) for the tre... | |
The effect of concurrent health conditions on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd). | The median progression-free survival (PFS) for the treatment combination of Panobinostat+Bortezomib+Dexamethasone (Pano-Vd) from PANORAMA-1 was 11.99 months with a 95% Confidence Interval (CI) of (10.33, 12.94) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Panobinostat+Bortezomib+Dexamethasone (Pano-Vd).
### Response:
The median progression-free survival (PFS) for the treatment combina... | |
Median PFS for Placebo+Bortezomib+Dexamethasone (Vd)? | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Placebo+Bortezomib+Dexamethasone (Vd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-... | |
Comparison of the median PFS for Placebo+Bortezomib+Dexamethasone (Vd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Placebo+Bortezomib+Dexamethasone (Vd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Plac... | |
The impact of patient characteristics on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo... | |
The role of genetic factors in the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomi... | |
The influence of previous treatments on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo+... | |
The effect of dosage and administration frequency on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).
### Response:
The median progression-free survival (PFS) for the treatment combinatio... | |
The correlation between the median PFS for Placebo+Bortezomib+Dexamethasone (Vd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Placebo+Bortezomib+Dexamethasone (Vd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination ... | |
The impact of side effects and adverse reactions on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).
### Response:
The median progression-free survival (PFS) for the treatment combination... | |
The role of supportive care in improving the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo... | |
The influence of disease stage at the start of treatment on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).
### Response:
The median progression-free survival (PFS) for the treatment com... | |
The effect of concurrent health conditions on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Bortezomib+Dexamethasone (Vd) from PANORAMA-1 was 8.08 months with a 95% Confidence Interval (CI) of (7.56, 9.23) <sup>[1](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(14)70440-1/fulltext)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Placebo+Bortezomib+Dexamethasone (Vd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Pl... | |
Median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd)? | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) ... | |
Comparison of the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination ... | |
The impact of patient characteristics on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).
### Response:
The median progression-free survival (PFS) for the treatment combination of ... | |
The role of genetic factors in the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Dexamethas... | |
The influence of previous treatments on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).
### Response:
The median progression-free survival (PFS) for the treatment combination of D... | |
The effect of dosage and administration frequency on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).
### Response:
The median progression-free survival (PFS) for the treatment com... | |
The correlation between the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combi... | |
The impact of side effects and adverse reactions on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).
### Response:
The median progression-free survival (PFS) for the treatment comb... | |
The role of supportive care in improving the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).
### Response:
The median progression-free survival (PFS) for the treatment combination of ... | |
The influence of disease stage at the start of treatment on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).
### Response:
The median progression-free survival (PFS) for the treatm... | |
The effect of concurrent health conditions on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd). | The median progression-free survival (PFS) for the treatment combination of Dexamethasone+Lenalidomide+Carfilzomib (KRd) from ASPIRE was 26.1 months with a 95% Confidence Interval (CI) of (23.2, 30.3) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Dexamethasone+Lenalidomide+Carfilzomib (KRd).
### Response:
The median progression-free survival (PFS) for the treatment combinatio... | |
Median PFS for Lenalidomide+Dexamethasone (Rd)? | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Lenalidomide+Dexamethasone (Rd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 month... | |
Comparison of the median PFS for Lenalidomide+Dexamethasone (Rd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Lenalidomide+Dexamethasone (Rd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomi... | |
The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+... | |
The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethas... | |
The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+D... | |
The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of L... | |
The correlation between the median PFS for Lenalidomide+Dexamethasone (Rd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Lenalidomide+Dexamethasone (Rd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Len... | |
The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Le... | |
The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+... | |
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combinati... | |
The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ASPIRE was 16.6 months with a 95% Confidence Interval (CI) of (14.5, 19.4) <sup>[1](https://jhoonline.biomedcentral.com/articles/10.1186/s13045-018-0583-7)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalido... | |
Median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd)? | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) fr... | |
Comparison of the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination o... | |
The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).
### Response:
The median progression-free survival (PFS) for the treatment combination of L... | |
The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomid... | |
The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Le... | |
The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).
### Response:
The median progression-free survival (PFS) for the treatment comb... | |
The correlation between the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combin... | |
The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).
### Response:
The median progression-free survival (PFS) for the treatment combi... | |
The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).
### Response:
The median progression-free survival (PFS) for the treatment combination of L... | |
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).
### Response:
The median progression-free survival (PFS) for the treatme... | |
The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone+Elotuzumab (ERd) from ELOQUENT-2 was 19.4 months with a 95% Confidence Interval (CI) of (16.6, 22.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone+Elotuzumab (ERd).
### Response:
The median progression-free survival (PFS) for the treatment combination... | |
Median PFS for Lenalidomide+Dexamethasone (Rd)? | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Lenalidomide+Dexamethasone (Rd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 m... | |
Comparison of the median PFS for Lenalidomide+Dexamethasone (Rd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Lenalidomide+Dexamethasone (Rd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomi... | |
The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+... | |
The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethas... | |
The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+D... | |
The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of L... | |
The correlation between the median PFS for Lenalidomide+Dexamethasone (Rd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Lenalidomide+Dexamethasone (Rd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Len... | |
The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Le... | |
The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalidomide+... | |
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combinati... | |
The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Lenalidomide+Dexamethasone (Rd) from ELOQUENT-2 was 14.9 months with a 95% Confidence Interval (CI) of (12.1, 17.2) <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1505654)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Lenalido... | |
Median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd)? | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from T... | |
Comparison of the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of ... | |
The impact of patient characteristics on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixa... | |
The role of genetic factors in the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lena... | |
The influence of previous treatments on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixaz... | |
The effect of dosage and administration frequency on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).
### Response:
The median progression-free survival (PFS) for the treatment combin... | |
The correlation between the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combinat... | |
The impact of side effects and adverse reactions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).
### Response:
The median progression-free survival (PFS) for the treatment combina... | |
The role of supportive care in improving the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Ixa... | |
The influence of disease stage at the start of treatment on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).
### Response:
The median progression-free survival (PFS) for the treatment... | |
The effect of concurrent health conditions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd). | The median progression-free survival (PFS) for the treatment combination of Ixazomib+Lenalidomide+Dexamethasone (IRd) from TOURMALINE-MM1 was 20.6 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Ixazomib+Lenalidomide+Dexamethasone (IRd).
### Response:
The median progression-free survival (PFS) for the treatment combination o... | |
Median PFS for Placebo+Lenalidomide+Dexamethasone (Rd)? | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Placebo+Lenalidomide+Dexamethasone (Rd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURM... | |
Comparison of the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Pl... | |
The impact of patient characteristics on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Place... | |
The role of genetic factors in the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalid... | |
The influence of previous treatments on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Placeb... | |
The effect of dosage and administration frequency on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combinat... | |
The correlation between the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combinatio... | |
The impact of side effects and adverse reactions on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combinati... | |
The role of supportive care in improving the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Place... | |
The influence of disease stage at the start of treatment on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment c... | |
The effect of concurrent health conditions on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd). | The median progression-free survival (PFS) for the treatment combination of Placebo+Lenalidomide+Dexamethasone (Rd) from TOURMALINE-MM1 was 14.7 months with a 95% Confidence Interval (CI) of None <sup>[1](https://www.nejm.org/doi/10.1056/NEJMoa1516282)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Placebo+Lenalidomide+Dexamethasone (Rd).
### Response:
The median progression-free survival (PFS) for the treatment combination of ... | |
Median PFS for Carfilzomib+Dexamethasone (Kd)? | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Carfilzomib+Dexamethasone (Kd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 month... | |
Comparison of the median PFS for Carfilzomib+Dexamethasone (Kd) with other treatment regimens. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Comparison of the median PFS for Carfilzomib+Dexamethasone (Kd) with other treatment regimens.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib... | |
The impact of patient characteristics on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of patient characteristics on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+De... | |
The role of genetic factors in the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of genetic factors in the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethason... | |
The influence of previous treatments on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of previous treatments on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dex... | |
The effect of dosage and administration frequency on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of dosage and administration frequency on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Ca... | |
The correlation between the median PFS for Carfilzomib+Dexamethasone (Kd) and overall survival rates. | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The correlation between the median PFS for Carfilzomib+Dexamethasone (Kd) and overall survival rates.
### Response:
The median progression-free survival (PFS) for the treatment combination of Carf... | |
The impact of side effects and adverse reactions on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The impact of side effects and adverse reactions on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Car... | |
The role of supportive care in improving the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The role of supportive care in improving the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzomib+De... | |
The influence of disease stage at the start of treatment on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The influence of disease stage at the start of treatment on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combinatio... | |
The effect of concurrent health conditions on the median PFS for Carfilzomib+Dexamethasone (Kd). | The median progression-free survival (PFS) for the treatment combination of Carfilzomib+Dexamethasone (Kd) from ENDEAVOR was 18.7 months with a 95% Confidence Interval (CI) of (15.6, NE) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
The effect of concurrent health conditions on the median PFS for Carfilzomib+Dexamethasone (Kd).
### Response:
The median progression-free survival (PFS) for the treatment combination of Carfilzom... | |
Median PFS for Bortezomib+Dexamethasone (Vd)? | The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months with a 95% Confidence Interval (CI) of (8.4, 10.4) <sup>[1](https://clinicaltrials.gov/ct2/show/results/NCT01568866)</sup> | Below is an instruction that describes a task. Write a response that appropriately completes the request.
### Instruction:
Median PFS for Bortezomib+Dexamethasone (Vd)?
### Response:
The median progression-free survival (PFS) for the treatment combination of Bortezomib+Dexamethasone (Vd) from ENDEAVOR was 9.4 months w... |
End of preview. Expand in Data Studio
README.md exists but content is empty.
- Downloads last month
- 4